Another success story of cured Liver Cirrhosis by Kamalahar!

Mr. Sandeep, a resident of New Delhi who was suffering from severe alcoholic liver cirrhosis and got cured within six months of starting the treatment of our Ayurvedic medicine, Kamalahar.

Usually, Doctors say that there is no allopathic cure for this disease but we say otherwise and so does Mrs. Mamta, wife of Mr. Sandeep who had lost all hopes to be cured by any sort of treatment other than an option of Liver transplant. They had diagnosed about his sickness only when his belly suddenly started to grow big unexpectedly because of the liver cirrhosis and he went through various treatments for three months which all went into vain. Doctors had given a month time until they kept her husband under observation because of his weakness for the transplant. This is when she somehow got to know about Kamalahar from a relative of hers and researched more about it online on our website and started giving the medicine to her husband once he was out from the ICU.

They started noticing betterment within one to two months of starting the Kamalahar treatment. Mrs. Mamta mentioned that the serum bilirubin was 18-22 at the worst stage which started dropping with two points and continued dropping till even four points within a gap of fifteen days as she went for his regular check-ups. Other symptoms improved as well, like the yellowish skin tone and the yellowish colour in the eyes started coming back to its normal state. The medicine dosage of two capsules a day was reduced to one per day along with the improvement of the patient.

Now after getting totally cured by Kamalahar, she says she recommends this product to as many friends and relatives as possible whenever she gets to hear of some similar liver problems and would like more and more people to know about this ayurvedic medicine for the benefits it carries along with it.

Breath test analyzer could help detect liver disease at early stage

In the journal EBioMedicine, a study led by the University of Birmingham in the UK suggests that high levels of a natural compound called limonene in the breath could be a sign of early-stage cirrhosis of the liver.

Researchers say that we already know that the breath of people with liver disease has a very distinct smell, and they wanted to find out what causes it. Now they have found a biomarker for the disease in limonene, they can continue to verify how good it is for diagnosing liver disease.

Limonene is a natural compound found in fruits and vegetables and in abundance in citrus fruits like oranges and lemons. It is also found in cosmetics, perfume and cleaning products and is used to flavor candies.

Because symptoms tend to be vague and often mild during the early stages, patients with liver disease do not usually seek medical advice until the condition is advanced and the liver is more damaged. Even then, symptoms can be mistaken for other diseases. They can include fatigue, jaundice, bleeding, swelling, bruising easily, confusion and nausea.

Cirrhosis is where continuous, long-term damage causes the liver to become so scarred it cannot function properly. The disease can lead to liver failure and cancer.

In the UK, where the new study took place, liver disease has risen sharply in recent decades to become the third biggest cause of early death, with 75% of deaths being alcohol related.

Breath levels of limonene higher in patients with liver cirrhosis

Researchers carried out their study in two phases. First, they compared breath samples from 31 patients with liver cirrhosis with those from 30 healthy controls.

In the second phase, they compared breath samples taken before and after liver transplants. The before samples came from the same 31 patients as in the first phase, and the after samples came from 11 of those patients who went on to have liver transplants.

The breath samples were analyzed with a mass spectrometer. For phase 1, this showed that the level of limonene in the patients with liver cirrhosis were much higher than in the healthy controls.

The researchers say this is probably because a diseased liver cannot fully metabolize limonene.

The phase 2 analysis showed that the levels of limonene gradually dropped in the transplant patients in the days following receipt of their new organ.

Limonene is 'unambiguously associated with diseased liver'

There have been previous attempts to find possible biomarkers for liver disease but these have suggested compounds like isoprene and acetone, which are not specific enough since they can also be indicative of other diseases or even arise naturally from normal metabolic activity.

Researchers wanted to find a biomarker that is unambiguously associated with diseased liver. If the further research is successful, in the future we can envisage a small portable breath analyser that can be used by GPs and other health professionals to screen for early-stage liver disease, leading to earlier treatment and better survival rates.

A particularly important advantage of breath tests is that they offer the opportunity to assess the global function of the liver, rather than a localized test such as biopsy.

The study is important, because for the first time it opens a potential route to noninvasive, real-time detection of early-stage liver disease. The researchers conclude that If that is possible, then the disease could be reversed by drugs and lifestyle change which would lead to major socioeconomic impacts.

Liver disease on the rise in Pakistan

Approximately, one in nine Pakistanis suffer from a liver disease, as stated by a liver transplant expert. The number of patients with liver problems is on the rise in Pakistan. There are over 300,000 patients in the country in need of a new liver and 80 to 90 per cent liver disease patients suffer from hepatitis.
Some patients have Wilson’s disease and others had alcohol-related problems. Constant lethargy, darkening complexion, fever, vomiting blood and accumulation of fluid in the abdominal cavity are frequent symptoms of liver disease. The survival rate of a patient suffering from a liver disease varies and if a liver disease remained untreated, the patient could expire in six years. 

Genes Associated With Unhealthy Liver Function

A groundbreaking study of nearly 2,300 extremely obese diabetes patients has identified genes associated with unhealthy liver function.

This is believed to be one of the first large-scale genome-wide association study in overweight patients with diabetes.Results of the study will be presented at the 64th annual meeting of the American Association for the Study of Liver Diseases Nov. 1-5 in Washington, D.C.

The study -- Genome-wide analysis identifies loci associated with total bilirubin levels, steatosis, and mild fibrosis in nonalcoholic fatty liver disease -- looked at how genomic factors affect the development of non-alcoholic fatty liver disease. It was selected for presentation from among a record 3,139 submittals from around the world proposed for what also is known as The Liver Meeting 2013.

These genetic factors could help us identify patients who are most at risk of developing non-alcoholic forms of fatty-liver disease (NAFLD), and which patients may be more likely to progress to severe forms of NAFLD, such as steatohepatitis (NASH). NAFLD is the build up of extra fat in liver cells, not caused by alcohol. It is one of the most common causes of chronic liver disease. NASH is liver inflammation and damage caused by a buildup of fat in the liver, not caused by alcohol. The researchers discovered genes that may help identify those patients most at risk for the types of liver disease so severe that they could require transplants.

Imaging technique can help detect liver disease in children without need for needle biopsy

A new, non-invasive imaging technique, magnetic resonance elastography (MRE), can now help physicians accurately detect fibrosis (scarring) in children with chronic liver disease – a growing problem due in part to increasing obesity rates.

A new study shows that MRE detects such chronic diseases as non-alcoholic fatty liver disease (NAFLD), which is increasingly common in children and teens, affecting an estimated 13 percent of adolescents. NAFLD can lead to progressive liver disease and liver failure. Obesity is a major risk factor. Because many pediatrics patients in the United States with NAFLD are severely obese, MRE is likely to be superior to ultrasound-based elastography in this population, as ultrasound-based methods are less reliable in severely obese patients.

If the findings are validated in larger studies, MRE could reduce dependence on costly and invasive liver biopsies to detect fibrosis. In 2011 and 2012, the researchers evaluated 35 children and teens between the ages of 4 and 20 for chronic liver disease using both MRE and liver biopsy. The study demonstrated that MRE was highly accurate in detecting more advanced fibrosis in children with chronic liver disease, including severely obese patients.

A needle biopsy is standard practice for evaluating liver fibrosis. This not only has risks for the patient and high expense, but it is often frightening for children and teens. MRE is a way to measure tissue stiffness that uses low frequency sound waves in combination with magnetic resonance, which involves the combination of magnetic fields and radio frequency waves to produce diagnostic images. MRE can be accomplished in just a few minutes using the MR scanner. Having the ability to easily and non-invasively assess the degree of fibrosis in a child’s liver could help to identify the issue early and take the right course of treatment in a timely and effective manner. An added strength of magnetic resonance technology is the ability to more precisely measure liver fat, which allows to non-invasively determine changes in liver fat quantity after clinical interventions.

The results so far show the potential of MRE to improve clinical care and reduce dependence on liver biopsies, but it is not yet ready for primetime clinical use. In addition to validation in larger pediatric cohorts, we still need to determine whether MRE can predict changes in liver disease over time. The researchers hope to study MRE in patients to test how well changes in imaging correlate with changes in liver stiffness after treatment or lifestyle changes.